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Abstract
Tumor treating fields (TTFields) is a new modality used for the treatment of glioblastoma. It
is based on antineoplastic low-intensity electric fields induced by two pairs of electrode
arrays placed on the patient’s scalp. The layout of the arrays greatly impacts the intensity
(dose) of TTFields in the pathology. The present study systematically characterizes the
impact of array position on the TTFields distribution calculated in a realistic human head
model using finite element methods. We investigate systematic rotations of arrays around a
central craniocaudal axis of the head and identify optimal layouts for a large range of (nine-
teen) different frontoparietal tumor positions. In addition, we present comprehensive graphi-
cal representations and animations to support the users’ understanding of TTFields. For
most tumors, we identified two optimal array positions. These positions varied with the trans-
lation of the tumor in the anterior-posterior direction but not in the left-right direction. The two
optimal directions were oriented approximately orthogonally and when combining two pairs
of orthogonal arrays, equivalent to clinical TTFields therapy, we correspondingly found a
single optimum position. In most cases, an oblique layout with the fields oriented at forty-five
degrees to the sagittal plane was superior to the commonly used anterior-posterior and left-
right combinations of arrays. The oblique configuration may be used as an effective and via-
ble configuration for most frontoparietal tumors. Our results may be applied to assist clinical
decision-making in various challenging situations associated with TTFields. This includes
situations in which circumstances, such as therapy-induced skin rash, scar tissue or shunt
therapy, etc., require layouts alternative to the prescribed. More accurate distributions
should, however, be based on patient-specific models. Future work is needed to assess the
robustness of the presented results towards variations in conductivity.
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Introduction
Glioblastoma multiforme (GBM) is a devastating brain cancer with an incidence of approxi-
mately 3-4/100.000 [1]. Standard therapy includes maximal safe resection of the tumor fol-
lowed by radio-chemotherapy [2–8]. In addition, tumor treating fields (TTFields) are
increasingly being used as a supplementary treatment modality for both recurrent and newly
diagnosed GBM [9–12]. TTFields are low intensity (1–3 V/m) intermediate frequency (200
kHz) alternating electrical fields, which inhibit tumor growth. Clinical trials with TTFields
have demonstrated promising results [13–19]. For recurrent GBM, the technology performs as
well as best physicians’ choice chemotherapy but is associated with far less discomfort and
adverse events [13]. For newly diagnosed GBM, TTFields increase the median overall survival
by approximately five months when applied in addition to standard radio-chemotherapy
[14,17,19–21]
TTFields are generated by two pairs of 3x3 electrode arrays placed on the scalp of the
patient so that the fields induced by each pair are presumably orthogonal. Each pair of arrays
is supplied by a portable and battery-powered current source carried by the patient. The
sources are activated in sequence so when one source is active, the other is inactive and vice-
versa. Each source has a repeated 50% square (on/off) duty-cycle of 2 s total duration, i.e.
within one duty-cycle the source is active for 1 s, and then inactive for 1 s. During activation,
each source induces a 200 kHz sinusoidal alternating field and the maximum peak-to-peak
current delivered is 1.8A. The current level is controlled to maintain a skin temperature below
41˚C. The therapeutic benefit depends on user compliance and the device “on-time” and the
device should be active for at least 18 hours per day [22] (https://www.optune.com/content/
pdfs/Optune_PIOM_8.5x11.pdf).
The mechanism of action of TTFields is believed to relate mainly to direct physical interfer-
ence with the mitotic process, such as septin and tubulin assembly and also direct migration of
polarized particles in dividing cells [23–25]. Previous in vitro studies have established a signifi-
cant dependency between the intensity of the induced field and the degree of tumor growth
reduction [23,24]. The lower threshold of inhibition was determined to be 100 V/m while field
intensities higher than 225 V/m induced tumor regression. Given this significant dose-
response relationship, it is clear that the distribution of TTFields inside the head, brain, and
tumor plays an important role for the expected treatment benefit for each patient. Therefore,
methods to quantify this distribution are highly warranted, and recent studies have described
various approaches to achieve this goal using finite element (FE) methods [26–36]. In a recent
study, MRI data from a GBM patient were used to produce an accurate head FE model allow-
ing for precise representation of the individual anatomy and dielectric property distribution.
The approach was used to investigate the potential enhancement of TTFields using craniect-
omy and skull remodeling surgery to create paths for current flow directly into the tumor. In
another study, a head model was constructed from MRI data of a healthy individual. The
model was modified to incorporate virtual pathologies by post-processing of the head mesh
[36] and used to identify general factors affecting the distribution of TTFields, such as tumor
position, the type of surrounding tissue, and the presence of central necrosis in the tumor.
Despite the increasing focus on understanding the biophysics of TTFields, several questions
remain unanswered. In this study, we will utilize a virtual lesion FE approach similar to the one
described above to systematically investigate the impact of electrode position on the TTFields
distribution and the average dose of TTFields experienced by tumors spanning a large range of
the hemispheric regions. We will investigate the impact of systematic rotation of the transducer
array pairs around a central craniocaudal axis of the head to investigate optimal configurations
and transducer array layouts for various tumor locations. As a novel and significant finding, we
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will show that an oblique array layout is superior to the standard left-right (LR) and anterior-
posterior (AP) array layout for many tumor locations. Furthermore, our results will provide sys-
tematic and direct visual and quantitative information on the impact of electrode movement on
the TTFields distribution. This information is highly important for clinicians and users who
often have to adapt TTFields therapy and electrode layout to counter common challenges, such
as therapy-induced skin rash beneath the electrodes. We hope to support users and clinicians to
gain a better understanding of the TTFields therapy treatment and thereby aid treatment plan-
ning and optimize the clinical implementation of the technology.
Methods
Field calculations
We calculated the electric field distribution in a realistic model of a human head using a finite
element (FE) approximation of the electric potential [26,27,33,35–38]. In general, the quantities
defining a time-varying electromagnetic field are given by the complex Maxwell equations [39].
However, in biological tissues and at the low to intermediate frequency of TTFields (f = 200kHz),
the electromagnetic wavelength is much larger than the size of the head and the electric permit-
tivity ε is negligible compared to the real-valued electric conductivity σ, i.e. oε
s
 1, where ω =
2πf is the angular frequency [40]. This implies that the electromagnetic propagation effects and
capacitive effects in the tissue are negligible, so the scalar electric potential φ may be well approx-
imated by the static Laplace equationr(σrφ) = 0, with appropriate boundary conditions at the
electrodes and skin [26,31,40,41]. Thus, the complex impedance is treated as resistive (i.e. reac-
tance is negligible) and currents flowing within the volume conductor are, therefore, mainly free
(Ohmic) currents. The validity of this approximation for TTFields has further been established
by Wenger et al., 2015 [31], who showed that permittivity affects the intensity of the resulting
field distribution in a realistic human head model by less than 2%. Similar observations were
recently made by Lok et al., 2017 [33]. Therefore, we have adopted the simpler electrostatic
approximation in this study. We would like to note that, while this approach is valid for the esti-
mation of the macroscopic field distribution in the head volume conductor, capacitive effects of
the cell membranes have to be taken into account when modelling the penetration of the external
current flow into tumor cells on the microscopic level [30,42]. However, the latter is not the
topic of this study. The FE approximation of Laplace’s equation was calculated using the Sim-
NIBS software (www.simnibs.org) [43]. Computations were based on the Galerkin method [44]
and the residuals for the conjugate gradient solver were required to be<1E−9. Dirichlet bound-
ary conditions were used with the electric potential was set to (arbitrarily chosen) fixed values at
each set of electrode arrays [45,46]. The electric (vector) field was calculated as the numerical
gradient of the electric potential and the current density (vector field) was computed from the
electric field using Ohm’s law. The potential difference of the electric field values and the current
densities were linearly rescaled to ensure a total peak-to-peak amplitude for each array pair of
1.8 A, calculated as the (numerical) surface integral of the normal current density components
over all triangular surface elements on the active electrode discs. This corresponds to the current
level used for clinical TTFields therapy by the Optune1 device. The “dose” of TTFields was cal-
culated as the intensity (L2 norm) of the field vectors. We assumed the modeled current to be
provided by two separate and sequentially active sources each connected to a pair of 3x3 trans-
ducer arrays (see below). The left and posterior arrays were defined to be sources in the simula-
tions, while the right and anterior arrays were the corresponding sinks, respectively. However, as
TTFields employ alternating fields, this choice is arbitrary and does not influence the results.
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Head model generation and positioning of tumors and arrays
A realistic head model was constructed from MRI data from a healthy individual (almi5 data-
set available at simnibs.org). The computational head mesh was initially segmented into skin,
bone, cerebrospinal fluid (CSF), gray matter (GM) and white matter (WM). To ensure system-
atic positioning of tumors and electrode arrays, we defined a right-handed reference coordi-
nate system in the model (Fig 1). We kindly refer the reader to Korshoej et al. (2017) for a full
description of how this coordinate system was constructed [36]. In summary, a transversal
plane was initially defined by conventional LR and AP positioning of the arrays. The left-right
direction was defined as the x-axis, the AP direction as the y-axis, and the cranio-caudal direc-
tion normal to the xy-plane was defined as the z-axis.
After defining the coordinate system, nineteen spherical tumors were placed at systematically
varying x, y and z coordinates to obtain a wide and clinically relevant range of cortical and sub-
cortical tumor positions in the frontal, parietal, and occipital regions of the right hemisphere
(Fig 1A). Tumor lesions were translated along the defined axes around a central position at the
frontoparietal junction (corresponding to x = 40 mm, y = 0 mm, z = 0 mm, see Fig 1). The exact
tumor coordinates are stated in the caption of Fig 1 and the intersecting surfaces of all tumors
are shown in Fig 1A and 1B along with corresponding x- and y-coordinate axes (z = 0). Tumor
lesions had external radii of 10 mm and inner core radii of 7 mm defining a core of central
necrosis, as previously investigated by the Authors and by Miranda et al. [26,28,31].
Electrode arrays consisted of nine electrodes of 20 mm diameter arranged in a 3x3 array
structure. The center-to-center distances between neighboring electrodes were 45 mm and 22
mm, respectively (Fig 1C). The transducer array configuration corresponded entirely to the
Optune™ technology, which is used for clinical treatment. Transducer arrays were placed with
their centers and longitudinal axes in the xy-plane. A pair of arrays was systematically rotated
around the z-axis of the head model, i.e. in the xy-plane, from 0 to 180 degrees, thereby cover-
ing the entire circumference of the head (by symmetry). The rotation interval was 15 degrees,
Fig 1. Visualization of coordinate system, tumor locations and electrode rotation. A. Axial section in the xy-plane of the GM and WM
surface of the head model with all tumor locations superimposed (radiological orientation). X- and y-axes are shown to illustrate tumor
center coordinates in millimeters. The tumor position x = 40 mm, y = 0 mm, and z = 0 mm is indicated by a solid arrow. All tumors were
located in the electrode plane, i.e. z = 0 mm and had the following x- and y-coordinates: X-translations (mm): (30, 0, 0), (32.5, 0, 0), (35, 0, 0),
(37.5, 0, 0), (42.5, 0, 0), (45, 0, 0), (47.5, 0, 0), (50, 0, 0). Y-translations (mm): (40, -40, 0), (40, -30, 0), (40, -25, 0), (40, -20, 0), (40, -10, 0), (40,
5, 0), (40, 10, 0), (40, 15, 0), (40, 20, 0), (40, 25, 0), (40, 30, 0). B. Same section as shown in panel A, but with illustrations of the tested electrode
rotations in the xy-plane from 0 to 180 degrees at 15-degree intervals. C. Surface view of the head model with one electrode array pair in the
AP position, i.e. 0 degrees. The x-, y-, and z- axes are shown along with a schematic illustration of the rotations path of the electrode arrays on
the skin.
https://doi.org/10.1371/journal.pone.0201957.g001
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corresponding to approximately 2 cm translations, giving a total of twelve different positions
in the range of 180 degrees (Fig 1C). Calculations were performed for electrode positions at all
tumor locations.
Isotropic conductivity estimates corresponded to previous in vivo measurements at compa-
rable frequencies [47–49]. Anisotropic conductivity tensor estimates were obtained for GM
and WM using diffusion MRI and a linear direct mapping technique [50]. This mapping line-
arly rescales the diffusion tensors by a common factor to obtain the conductivity tensors. The
scaling factor is chosen so that the geometric mean of the eigenvalues of the conductivity ten-
sors fits as well as possible in a least-squares sense to isotropic reference values (0.276 S/m for
GM, and 0.126 S/m for WM). For the remaining tissue types, the following isotropic conduc-
tivities were used: Tumor 0.24 S/m, necrosis 1.00 S/m, skin 0.25 S/m; bone 0.010 S/m; and CSF
1.654 S/m. These values are based on average values obtained from in vitro and in vivo experi-
ments at comparable frequencies [51–54]. Additional detailed information about the methods
used in this study can be found in Korshoej et al., 2016 [35], and 2017 [36].
Results
Effect of array rotation
We investigated the impact of array rotation separately for tumors whose positions were varied
along the x- and y-axes, respectively. Two-dimensional color maps were created to visualize
the effect of rotation for different tumor positions systematically along each of the two axes. As
previously described, TTFields therapy in its current form (Optune™) is applied using two
sequentially active array pairs oriented orthogonally to each other. This is done to distribute
the effect across cells dividing in different directions because the effect is higher when the field
is applied in the direction of cell division [23]. To assess clinically relevant layout configura-
tions, we, therefore, combined the results of all sets of array pairs oriented orthogonally to
each other by calculating the average field induced by the two orthogonal pairs in the tumor
tissue. This is equivalent to calculating the average peak field in the tumor over one duty cycle
of TTFields for the given configuration and allows for direct efficacy assessment of orthogonal
array configurations at different rotations around the head. The results are presented as both
color maps as well as visual field maps showing the strength of the induced field in representa-
tive sections of the head model.
Tumors translated in the left-right direction (x-axis)
The median field intensity in the tumor varied considerably with tumor location and array
position (Fig 2). For all tumor locations, the direct AP array position at θ = 0 and 180 degrees
induced the lowest median field strength (E = 131 to 148 V/m). For tumors located in the cor-
tical region, i.e. superficial to the sulcal fundi at x = 37.5 to 50 mm, the field intensity showed
two maxima at the oblique orientations of θ = 45 degrees (E = 165–193 V/m) and θ = 135
degrees (E = 172–195 V/m), respectively. This phenomenon is illustrated in Fig 2A. The field
was slightly lower (E = 155–170 V/m) for the LR array orientation, θ = 90 degrees. For tumors
in the deeper subcortical regions (x = 30 to 35 mm), the field showed a smooth curve with a
single maximum at θ = 90 degrees (E = 179–209 V/m). The field intensity at θ = 90 degrees
increased for deeper tumor positions. Array positions at θ = 45 to θ = 135 degrees also induced
high mean field intensities comparable to θ = 90 degrees. Fig 2C shows an example of the field
distribution for the subcortical position x = 30 mm. The supplementary material S1–S3 Videos
show additional animations of the changing field distributions for all array rotations at repre-
sentative tumor locations encompassing both cortical and subcortical positions, i.e. x = 30
mm, x = 42.5 mm, and x = 50 mm, respectively.
Identification of effective TTFields layouts for a wide range of tumor
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The average field strength induced by two orthogonal pairs of arrays was maximal at θ = 45
degrees, i.e. the combination of two oblique array pairs was superior to all other orthogonal com-
binations regardless of the tumor location along the x-axis (Fig 2D). In addition, S4 Video shows
an animation of the sequence of field distributions induced by the optimal combination of
orthogonal array pairs as the tumor is gradually translated from medial to lateral. As it is evi-
dent, the optimal array position is the oblique layout (θ = 45 degrees and θ = 135 degrees) for
all tumors along the x-axis. The average field for the oblique layout was between E = 183 V/m
Fig 2. Effect of array rotation on field intensity for left-right tumor translations on the x-axis. A. Color map of the median field
intensity (V/m) in the tumors at varying x-positions (30 mm to 50 mm, ordinate) and varying rotations (θ = 0 to 180 degrees, abscissa) of a
single pair of electrode arrays. Y- and z-coordinates were kept constantly at zero for all tumors, i.e. all tumors were in the center-to-center
plane of the rotated array pairs. The figure shows field maxima at θ = 45 and 135 degrees, respectively, for all tumors between x = 35 mm
and 50 mm, while deeper seated tumors experienced high fields for all rotations between these values. B. Axial section of the GM and WM
surfaces and the investigated tumors (x translations, i.e. x = 30 to 50 mm, y = 0 mm, and z = 0 mm). Array rotations and tumor locations
are indicated by the corresponding arrows and axis, respectively. C. Axial section (radiological convention) of the WM, GM and tumor
volume (x = 30 mm, position indicated by the solid arrow), showing an example of the topographical distribution of the field induced by
TTFields (left-right array position, θ = 90 degrees). D. Color map comparable to panel A, but illustrating the mean field induced by two
orthogonal array pairs. Tumor positions are indicated on the ordinate and the rotations of the posterior array on the abscissa (θ = 0 to 90
degrees). The figure shows a maximum mean field intensity at θ = 45 degrees equivalent to an oblique position of both pairs. The field
distribution of this “optimal” layout is shown in panel F for the tumor position x = 30 mm, while the distribution of the least effective
layout (θ = 0 degrees) for the same tumor is shown in panel E.
https://doi.org/10.1371/journal.pone.0201957.g002
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and E = 195 V/m depending on tumor position, and this corresponds to 9–23% enhancement
compared to the least effective standard AP/LR layout at θ = 0 and 90 degrees. Fig 2E and 2F
shows the topographical distribution of the average field for both the most effective array posi-
tion θ = 45/135 degrees and the least effective θ = 0/90 degrees, respectively, at the tumor posi-
tion (x = 30 mm). Animations of the average field distributions for combined orthogonal
arrays pairs are shown in the supplementary material S4–S6 Videos for all rotations and the
same representative tumor locations, x = 30 mm, x = 42.5 mm and x = 50 mm, as shown in
S1–S3 Videos.
Tumors translated in the anterior-posterior direction, y-axis
For most parietal and occipital tumors, i.e. y  0 mm, array positions between θ = 15 and θ
= 135 degrees all tended to perform well and induced relatively high field values (Fig 3). For
frontal tumors (i.e. y > 0 mm) there was a tendency towards higher field values for array
positions at θ = 60 degrees and higher. However, looking more closely at Fig 3, we see that
for most tumor positions in the anterior-posterior direction, there are two peaks in the plot
of median field strength against different array rotations (Fig 3A), as it was also observed
for cortical tumors translated in the left-right direction (see above). Correspondingly, the
peak values also occurred at approximately orthogonal array positions. However, the array
positions inducing peak field values varied with tumor location, as demonstrated in the
oblique tendency of peak median field values in the color map. This observation is further
illustrated in Fig 3D, which shows the average median field strength for all combinations of
two orthogonal pairs of electrode arrays. The figure shows, that for every tumor position, an
optimum position for each pair of orthogonal arrays exists. Furthermore, the optimum position
is gradually rotated as the tumor is moved in the anterior-posterior direction. This concept is
further animated in the supplementary material S8 Video, which shows the induced field
distribution by the optimal array position for all tumors along the y-axis. As a general obser-
vation, for all the tumors the optimal layout was angled at approximately 45 degrees to the
surface of the cortical region immediate overlying the tumor. Correspondingly, they were
also oriented at approximately 45 degrees to the sulcal/gyral border in the vicinity of the
tumor, as these were close to perpendicular to the brain surface. The field intensities
induced by the optimum array layouts were generally 10% to 17% higher relative to the lay-
out with the lowest efficacy. The oblique layout at θ = 45 degrees performed well for most
tumor locations and better than the AP/LR layout (θ = 0 and 90 degrees) for all cases.
Fig 3C shows an example of the field distribution at the single array position (θ = 90
degrees) which induced maximum field intensity for a selected tumor at y = -40 mm. Corre-
spondingly, Fig 3E and 3F show examples of the orthogonal combination of electrode layouts
with the highest (E = 183 V/m) and lowest mean field intensity (E = 167 V/m) for the same
tumor location, respectively. The supplementary material S9–S12 Videos, shows animations of
the field distributions induced by single rotating array pairs for tumor locations spanning a
large (7 cm) anterior-posterior range, i.e. y = -40 mm, y = -40 mm, y = -20 mm, y = 20 mm,
and y = 30 mm. The corresponding distributions of combined orthogonal arrays pairs (mean
field intensity) are shown in S13–S16 Videos for the same tumor positions, respectively.
Discussion
In this study, we used realistic head models and finite element calculations to compute the dis-
tribution of TTFields for a large number of transducer array layouts and tumor positions. Spe-
cifically, we have investigated the impact of systematic rotation of a pair of transducer arrays
around a central craniocaudal axis of the head on the dose of TTFields in nineteen
Identification of effective TTFields layouts for a wide range of tumor
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systematically varied tumor positions. We have identified optimum array positions for each
tumor position and presented elaborate animations and graphical representations to provide
users with a more intuitive understanding of the effect and distribution of TTFields and how
this depends on the tumor and electrode array position.
As general observations, we found that varying the array layout produced markedly differ-
ent field distributions and that the array position had a great impact (up to 23%) on the median
field intensity observed in the tumor region for all studied tumor positions. In particular,
Fig 3. Effect of array rotation on field intensity for anterior-posterior tumor translations, y-axis. A. Color map of the median field
intensity (V/m) in tumors at varying y-positions (-40 mm to 30 mm, ordinate) and varying rotations (θ = 0 to 180 degrees, abscissa) of a single
pair of electrode arrays. X- and z-coordinates were kept constant at x = 40 mm and z = 0 mm, respectively, for all tumors, i.e. all tumors were
in the center-to-center plane of the rotated array pairs. The figure shows field maxima at two separate rotations for the most tumors. The two
maxima were separated by approximately 90 degrees. B. Axial section of the GM and WM surfaces and the investigated tumors (y
translations, i.e. x = 40 mm, y = -40 to 30 mm, and z = 0 mm). Array rotations and tumor locations are indicated by the corresponding arrows
and the axis, respectively. C. Axial section (radiological convention) of the WM, GM and tumor volume (y = -40 mm, position indicated with
a solid arrow), showing an example of the topographical distribution of the field induced by TTFields (left-right array position, θ = 90
degrees). D. Color map comparable to panel A, but illustrating the mean field induced by two orthogonal array pairs. Tumor positions are
indicated on the ordinate and the rotations of the posterior array on the abscissa (θ = 0 to 90 degrees). The figure shows a single maximum of
the mean field intensity at varying rotations depending on the tumor of interest. The field distribution of the “optimal” layout is shown in
panel F for the tumor position y = -40 mm, while the distribution of the least effective layout (θ = 0 degrees) for the same tumor is shown in
panel E.
https://doi.org/10.1371/journal.pone.0201957.g003
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when varying the tumor from left to right (Fig 2A), there was a bimodal dependency between
the field intensity in the tumor and the array position, meaning that the field dose peaked at
two separate (optimal) array positions. This result was observed for most superficial tumor
positions in the cortical regions. In addition, the two optimal array positions were close to
orthogonal for most tumors, i.e. positioned at ninety-degree intervals to each other. In the
deeper subcortical regions, we observed a single optimum array position at which the field was
maximal (θ = 90 degrees), however, high field intensities were observed for a wide range (45 to
135 degrees) of electrode positions, and the optimum combination of two orthogonal field
pairs had a single peak at θ = 45 degrees as observed for the superficial tumors on the x-axis.
When varying the tumor position in the anterior-posterior direction, we observed a signifi-
cant dependency between the optimum array configuration and the tumor position. Specifi-
cally, the optimum position of the orthogonal pair of arrays was gradually shifted clock-wise as
the tumor was moved from posterior to anterior positions (viewed in radiological convention).
However, array positions between θ = 15 and 135 degrees were all relatively effective for most
parietooccipital tumors, while rotations of θ = 135 degrees or higher were generally more effec-
tive for frontal tumor locations.
Due to the size of the electrode arrays, superficial tumors in our simulations were close to
one of the outer electrode columns of an array for the oblique array orientations. It is interesting
to note that the fields in the more superficial brain regions tend to be stronger underneath the
outer electrodes than the central electrode of an array (see, e.g. S3 Video). This resembles the
well-known edge effect for large pad electrodes used in transcranial electric brain stimulation
[55], due to which the field is higher underneath the edges compared to the center of these elec-
trode pads. Here, given that all electrodes of a TTFields electrode array are connected to the
same channel and thus have the same electric potential, the same effect occurs and causes an
unequal distribution of the current strength across the electrodes, with the outer electrodes
tending to induce stronger currents into the underlying skin area (Fig 4 shows this exemplarily
for a spherical head model). This effect is influenced by the local tissue conductivities under-
neath the electrodes (e.g., thin vs. thick skull) and thus varies across array orientations. How-
ever, the simulation results indicate that it is observed for the majority of orientations. As a
consequence, when employing orthogonal pairs of arrays at an oblique orientation, superficial
tumors will be close to an outer electrode column of one of the arrays for each of the two pairs,
resulting in high median field strength. This explains the superiority of the 45˚ layout compared
to the standard LR and AP electrode montages for the superficial tumor positions when varying
the position from left to right. This effect is further increased by the generally low field intensity
caused by the AP electrode array pair (0 and 180 degrees in Fig 2A; please refer to Korshoej
et al. (2017) for a discussion of the reasons underlying the differences between LR and AP). The
enhanced field intensities underneath the outer electrode columns also explain the gradual shift
of the optimal array orientation when varying the tumor position from posterior to anterior.
This is exemplified by the superficial tumor location x = 50 mm (y = 0 mm and z = 0 mm),
which experienced the strongest fields at 45 degrees and 135 degrees, when the tumor was clos-
est to the anterior and posterior electrode columns, respectively, S3 Video. The reduction of
field intensity at angles between the two maxima (minimum at the left/right array position, Fig
2A) may also be explained in part by the edge effect because lower currents are induced under-
neath the central electrode. A likely contributing factor, however, is the fact that increasing
amounts of current are shunted through the sulci and thus pass the tumor when the field is ori-
ented increasingly in parallel with the sulci, i.e. close to the LR position.
The LR and AP configuration is a commonly employed layout for a wide range of tumors
In this study, we find that the vast majority of the investigated cases would benefit more from the
oblique configuration (45 degrees to the sagittal plane) than from the LR/AP array configuration,
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although even further optimization may be performed in accordance with the above results. Spe-
cifically, the field was maximized when the neighboring arrays were orthogonal and placed such
that their outermost columns of electrodes were close to the tumor. We found that each tumor
position was associated with a single optimum position of two orthogonal array pairs, at which
the induced field was highest. From a treatment efficacy point of view, the ninety-degree rela-
tionship between optimal array positions (bimodality, Figs 2A and 3A) is highly convenient.
This is because clinical TTFields therapy is performed with two orthogonal pairs of arrays in
order to target cells with a different (random) direction of mitosis and distribute the tumor-
inhibiting effect across larger regions of the pathology [23].
In general, our observations support the notion that the dose of TTFields, and therefore
expectedly also the therapeutic efficacy, depends significantly on the positioning of transducer
arrays on the scalp. Under normal circumstances, a personalized layout is produced for each
patient prior to treatment initiation, using the software NovoTAL™ (Novocure, Ltd.). Very
often, however, clinicians are faced with the challenge of having to deviate from the optimum
layout due to various circumstances, such as scar tissue, use of metallic bone-fixation implants
following surgery, or shunt therapy, etc. In addition, patients are recommended to move the
arrays by approximately 2 cm when they are changed every 3–4 days. This is done to minimize
the risk of skin rash beneath the electrodes, which is a commonly observed side effect of
TTFields therapy. Our results may be used to support clinicians and users in deciding optimal
Fig 4. ”Edge” effects for 3x3 electrode arrays. A. One of the two electrode arrays seen from above. B. Electric field distribution on the skin
surface. The higher field strengths at the outer edges of the electrode array are clearly visible. C. Electric field distribution on the GM surface. The
distribution is smoother than on the skin surface, but the lower field strengths underneath the array center are still clearly observed. D. Cut
through the spherical head model. It consists of a central WM sphere (r = 7.5 cm), surrounded by GM (outer r = 8.0 cm), CSF (outer r = 8.3 cm),
skull (outer r = 8.9 cm) and skin (outer r = 9.5 cm). The same tissue conductivities as for the head model were used, see Methods. GM and WM
were modelled as isotropic with σGM = 0.276 S/m and σWM = 0.126 S/m. E. Current flow in the plane shown in D. The lower current densities in
the skin and CSF layers underneath the central electrode are clearly observable (the different arrow densities in the sphere center are an artefact of
the meshing process and do not influence the results). F. Current flow in GM and WM in the same plane. The lower current densities in the GM
layer underneath the central electrode are clearly visible.
https://doi.org/10.1371/journal.pone.0201957.g004
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array layouts for patients undergoing therapy, when facing challenges as described above. Of
the tumors investigated, many would be treated with the LR and AP array layouts. This layout
is produced from FE calculations of the field distribution, based on field head models adapted
to the individual head and tumor morphometrics comparable to the approach used here. Our
results suggest that some patients may in fact benefit more from the oblique array layout or
layouts adapted in accordance with the above. In any case, the results presented provide viable
alternative layouts for a wide range of tumors.
Limitations and future perspectives
It is important to highlight that the investigated model reflects a limited, but comprehensive
variety of scenarios specific for the individual case. Although a large number of tumor and array
positions were investigated, personalized modeling experiments should ideally be conducted to
account for the complex individual variations in anatomy and (as far as possible) tissue conduc-
tivities, including the shape and size of the head and tumor, observed in real tumor patients.
Personalized approaches may account more accurately for the expected treatment efficacy and
support more precise, safe and efficacious treatment planning. In addition, personalized
approaches based on new and representative MRI data would enable a better and timelier char-
acterization of the TTFields distribution at the moment of interest. Thereby the model would
better account for changes, e.g. in tumor size or tissue composition, which may occur during
the course of TTFields treatment as a result of disease development or therapy. Recently, the
authors published an example of an individualized approach to TTFields modeling.
It should also be emphasized that the ohmic conductivity estimates used in the model
markedly influence the results of the field calculations (see Methods). Recent studies by Wenger
et al., 2015 [31], and Lok et al., 2017 [33], assessed the sensitivity of TTFields FEM models, such
as the one employed in this study, towards dielectric property variations. They conclude that the
conductivity variations significantly influence the distribution of TTFields, while permittivity
variations only play an insignificant role. In this study, we thus neglected the influence of per-
mittivity and have employed common conductivity values taken from the literature. However, it
should be emphasized that the biological tissue conductivities have not been firmly established
at 200 kHz, so that the resulting uncertainty might impact the generalizability of our results.
However, since the field changes observed with changing tumor and electrode position were pri-
marily associated with relative differences in conductivity between brain tissue, tumor tissue,
and CSF [36], the observations reported will likely hold for a range of conductivity variations, as
long as the differences in conductivity are in the same direction, i.e. the conductivity of CSF is
higher than the conductivity of tumor, and the conductivity of tumor is higher than the conduc-
tivity of brain tissue. Although the absolute field values will change with varying conductivities,
we expect that our main findings and conclusions will hold for a wide range of scenarios.
In addition to field intensity, future models should ideally also incorporate information
about exposure time and the amount of non-orthogonality (i.e., directional correlation) of the
electric fields that are induced by the two electrode array pairs in the tumor. The latter aspect
relates to the finding that the effects of TTFields on a dividing cancer cell are enhanced when
the field is aligned with the direction of cell division. Given that this direction varies randomly
across tumor cells, treatment efficacy seems to be improved when two or more oblique fields
rather than a single field direction are used [23]. Also, future models should incorporate better
segmentations of the pathology to obtain representative field estimates in the true regions of
interest. Finally, it is important to highlight that future consideration should also be given to
validating the simulation results by means of direct TTFields measurements in vivo.
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Conclusion
We present novel findings, describing the impact of systematic positional variation of TTFields
electrode arrays on a human head for a large number of tumor locations in the brain. For most
superficial tumor positions, we found that there were two optimal array positions, at which the
median field intensity was highest. These varied systematically (i.e. clockwise rotation), as the
tumor position was translated from posterior to anterior, while it was unaffected by left-right
tumor translations. In addition, the two optimal layouts were oriented approximately orthogo-
nally to each other. Correspondingly, we found that there was a single optimal layout of com-
bined orthogonal array pairs, at which the median TTFields dose was highest. The optimum
position also varied systematically in accordance with the above and in general, the optimum
arrays were oriented at 45 degrees to the surface of the brain immediately overlying the tumor.
We also found that one particular layout was more effective for most tumor locations com-
pared to the standard LR and AP combination of array pairs. This layout was composed of two
orthogonal and oblique array positions both oriented at 45 degrees to the mid-sagittal plane.
The presented results may generally guide layout configuration in clinical cases where devia-
tions from the suggested NovoTAL layout are required, e.g. due to therapy-induced skin rash,
etc. Furthermore, the oblique configuration may potentially be used as an effective, alternative
layout for most tumors although further optimization may be expected by direct comparison
with tumor representative locations. In addition, our results present extensive animations and
graphical representations, to illustrate the impact of tumor and electrode positions on the dis-
tribution of TTFields. Our results will hopefully improve users’ understanding of TTFields and
support clinical decisions on TTFields therapy.
The modeling approach used in this study is widely adopted. However, it must be noted
that variations in tissue conductivities and head morphology are likely to affect the results.
Further studies are required to estimate the robustness and sensitivity of the suggested conclu-
sions towards these variations. Also, accurate field estimation should ideally be computed
from patient-specific head models, which accurately represent the anatomy and tissue conduc-
tivity of the given individual.
Supporting information
S1 Video. Field distribution for rotation of a single array pair at the tumor position x = 30
mm.
(MP4)
S2 Video. Field distribution for rotation of a single array pair at the tumor position
x = 42.5 mm.
(MP4)
S3 Video. Field distribution for rotation of a single array pair at the tumor position x = 50
mm.
(MP4)
S4 Video. Field distribution of optimal array position for all tumors translated in the left-
right direction.
(MP4)
S5 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position x = 30 mm.
(MP4)
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S6 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position x = 42.5 mm.
(MP4)
S7 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position x = 50 mm.
(MP4)
S8 Video. Field distribution of optimal array position for all tumors in the anterior-poste-
rior direction.
(MP4)
S9 Video. Field distribution for rotation of a single array pair at the tumor position y = -
40 mm.
(MP4)
S10 Video. Field distribution for rotation of a single array pair at the tumor position y =
-20 mm.
(MP4)
S11 Video. Field distribution for rotation of a single array pair at the tumor position
y = 20 mm.
(MP4)
S12 Video. Field distribution for rotation of a single array pair at the tumor position
y = 30 mm.
(MP4)
S13 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position y = -40 mm.
(MP4)
S14 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position y = -20 mm.
(MP4)
S15 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position y = 20 mm.
(MP4)
S16 Video. Field distribution for orthogonal array pairs at various rotations and tumor
position y = 30 mm.
(MP4)
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